Tag: MYND Life Sciences - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article MYND Life Sciences Announces $3.5 Million Share Offering

MYND Life Sciences Announces $3.5 Million Share Offering

Post published:April 21, 2022
Post category:Press Release

Read more about the article MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

Post published:February 8, 2022
Post category:Press Release

Read more about the article MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

Post published:February 8, 2022
Post category:Press Release

Read more about the article MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Post published:January 12, 2022
Post category:Press Release

Read more about the article MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

Post published:December 17, 2021
Post category:Press Release

Read more about the article MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

Post published:December 15, 2021
Post category:Press Release

Read more about the article MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Post published:November 30, 2021
Post category:Press Release

Read more about the article MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Post published:November 18, 2021
Post category:Press Release

Read more about the article MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

Post published:November 16, 2021
Post category:Press Release

Read more about the article MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Post published:November 9, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.